Chronic gastrointestinal symptoms in Korean population
Scientists at Singapore’s Institute of Bioengineering and Nanotechnology (IBN) have uncovered new properties of imidazolium salts (IMSs), which suggest that they could play a vital role in disease prevention and treatment. The report on the redox properties of IMSs was published in the Journal of the American Chemical Society . In a separate study published
Full Post: Scientists discover new properties of imidazolium salts
Chronic gastrointestinal symptoms are highly prevalent in different geographic populations and cause various gastrointestinal symptoms that greatly inconvenience the lives of those affected.
Examples include GERD, uninvestigated dyspepsia, irritable bowel syndrome, and chronic constipation. These problems have an impact on the individual’s quality of life. There is a lack of community-based research evaluating the impact of chronic gastrointestinal symptoms on the quality of life.
A research article to be published on November7, 2008 in the World Journal of Gastroenterology addresses this issue. A research team led by Professor Choi and Jeong from The Catholic University of Korea performed a cross-sectional survey on randomly selected residents in Asan-Si, Korea. The authors assessed chronic gastrointestinal symptoms, using a Rome II based questionnaire. HRQOL was assessed using the Korean version of the SF-36. Of the 1807 eligible subjects, 1417 (78.4%: male 762; female 655) were surveyed, with a face-to-face interview.
The prevalence of gastroesophageal reflux disease (GERD), defined as heartburn and/or acid regurgitation experienced at least weekly, was 3.5. The prevalence of uninvestigated dyspepsia, irritable bowel syndrome (IBS) and chronic constipation, defined by Rome II criteria was 11.7%, 2.2%, and 2.6%, respectively. Compared with those not having chronic gastrointestinal symptoms (n = 1153), subjects with GERD (n = 50), uninvestigated dyspepsia (n = 166) and IBS (n = 31) had significantly worse scores on most domains of the SF-36 scales. The negative impact was greater in females, the elderly, subjects with a low economic class, and those with higher physician visits, and overlapping symptoms.
Based upon this research, it can be concluded that the quality of life was significantly impaired in subjects with GERD, uninvestigated dyspepsia and IBS. It can be reasoned that a better understanding of the impact of these disorders on all aspects of health, both mental and physical, may help in planning appropriate treatment interventions in these conditions.
According to new research conducted at Nationwide Children’s Hospital, the burden of illness in children suffering from constipation, and the costs associated with this condition, are roughly of the same magnitude as those for asthma and attention deficit-hyperactivity disorder (ADHD). These findings are a result of a study involving gastroenterologists and researchers at Nationwide Children’s
Full Post: Children with constipation a significant health issue
Although irritable bowel syndrome (IBS) is the most common disease diagnosed by gastroenterologists, it’s also one of the most misunderstood. That’s why updated guidelines addressing the management of the condition are being released by the American College of Gastroenterology. Through a comprehensive review of the latest medical research and expert consensus, the updated guidelines provide
Full Post: Updated guidelines for irritable bowel syndrome
AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old. GERD is a condition in which
Full Post: AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium)
Alfuzosin, a drug commonly prescribed for men with chronic prostatitis, a painful disorder of the prostate and surrounding pelvic area, failed to significantly reduce symptoms in recently diagnosed men who had not been previously treated with this drug, according to a clinical trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases
Full Post: Alfuzosin fails to reduce symptoms in chronic prostatitis
Two non-surgical, non-pharmacological treatments for gastroesophageal reflux disease (GERD) both appear effective in reducing medication use and improving voice and swallowing symptoms, according to a report in the January issue of Archives of Surgery. One type of therapy also appears effective for reducing heartburn and cough, whereas the other may be associated with a reduction
Full Post: Non-surgical, non-pharmacological treatments for gastroesophageal reflux disease compared